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Conjugation of ubiquitin regulates multiple pathways, including the signaling cascades leading to
antiviral immunity. Similarly, the ubiquitin-like peptide ISG15 mediates the antiviral response to certain
viruses. In this issue of Cell Host & Microbe, Frias-Staheli and colleagues demonstrate that research
on viral proteases of certain nairoviruses and arteriviruses reveals the presence of ovarian tumor
domain-containing sequences that act as general deubiquitinases and deISGylases and increase
viral replication by inhibiting the antiviral response mediated by ISG15.Coevolution of viruses and their natu-
ral hosts has provided these versatile
pathogens countless opportunities to
develop and diversify mechanisms of
evasion of the host immune response.
The innate immune response to vi-
ruses is in part regulated by the pro-
duction of type I interferon (IFN), a fam-
ily of cytokines that signals through its
cognate IFN receptors and the Janus
kinase (JAK)/signal transducer and
activator of transcription (STAT) path-
way, leading to the expression of hun-
dreds of genes with antiviral activity.
Detection of viral components by the
Toll-like receptor (TLR) system or the
cytoplasmic RNA helicases RIG-I and
Mda5 activates the IFN pathway by
signaling to the kinases IKK3/TBK1
to phosphorylate interferon regulatory
factors 3 and 7 (IRF3/IRF7) and induce
expression of IFN and IFN-stimulated
genes (ISGs) (Hiscott, 2007; Seth et al.,
2006). Simultaneously, the inflamma-
tory response is triggered through the
IkB kinase (IKK) complex, leading to
proteasomal degradation of the inhibi-
tor of NF-kB (IkB), release of NF-kB,and transcriptional stimulation of
NF-kB target genes (Hacker and Karin,
2006).
Activation and shutdown of these
two pathways is carefully orchestrated
by posttranslational modification
events. Although initial focus was di-
rected to phosphorylation events, it is
now clear that addition and removal
of ubiquitin chains is also a major reg-
ulatory mechanism that controls IRF
and NF-kB activation (Hacker and
Karin, 2006). Addition of K63-linked
ubiquitin chains—as in the case of
TRAF3 (TNF receptor-associated fac-
tor 3), TRAF6, and the IKK regulatory
subunits NEMO and RIG-I—generally
favors protein-protein interactions and
activation of downstream signaling.
Conversely, removal of K63-linked
chains negatively impacts NF-kB and
IRF activation. The deubiquitinase
(DUB) A20 is a negative regulator of
the classical NF-kB pathway that ter-
minates tumor necrosis factor a recep-
tor-, TLR-, and RIG-I-mediated NF-kB
activation (Wertz et al., 2004; Liu et al.,
2005). A20 also negatively regulatesthe IFN pathway following TLR3 or
RIG-I stimulation (Lin et al., 2006).
A20 belongs to the ovarian tumor
(OTU) domain DUBs—a family of pro-
teins that have been poorly character-
ized in terms of physiological function.
Very recently, the Dixit lab at Genen-
tech used a genome wide siRNA
screen to search for novel regulators
of interferon signaling and identified
DUBA (deubiquitinating enzyme A) as
a novel OTU-domain DUB that nega-
tively regulates IFN signaling follow-
ing RIG-I, Mda5, or TLR3 stimulation
(Kayagaki et al., 2007). DUBA specifi-
cally removed K63-linked ubiquitin
chains from TRAF3, resulting in the
disruption of interaction between
TRAF3 and the downstream kinases
IKK3 and TBK1 and blockade of IRF3
and IRF7 phosphorylation. Surpris-
ingly, DUBA had no effect on process-
ing of the NF-kB precursor NF-kB2/
p100 into the active subunit p52,
although TRAF3 is intimately involved
in the noncanonical NF-kB pathway.
Among the ISGs, ISG15 is a 15 kDa
protein that is able to covalentlyecember 2007 ª2007 Elsevier Inc. 367
Figure 1. Cellular Ubiquitination and ISGylation Are Inhibited by Viral OTU Domain
Deubiquitinases
Detection of viral infection by TLR-dependent and -independent mechanisms results in ubiquitina-
tion and ISGylation of numerous target proteins to induce the innate immune response. Conjuga-
tion of UB is mediated by the action of E1 and numerous E2 and E3 ubiquitin ligases, whereas
addition of ISG15 is mediated by the E1 enzyme UBE1L, Ubc8 (E2), and Herc5 (E3) (black arrows).
Targets of ubiquitination include retinoic acid inducible gene I (RIG-I), NF-kB essential modulator
(NEMO), receptor interacting protein-1 (RIP-1), and TNF-a receptor-associated factors (TRAF) 2,
3, and 6. Termination of this response is achieved by removal of ubiquitin (Ub) chains by the highly
specific deubiquitinases DUBA and A20, as well as removal of ISG15 chains by the deISGylase
UBP43 (thin red arrows). Viral OTU domain deubiquitinases (V-OTU) can nonspecifically cleave
ubiquitin and ISG15 chains from their respective targets (thick red arrows), thereby blocking the
generation of an antiviral state.
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same way as ubiquitin to induce an
antiviral state (Liu et al., 2005). Addition
of ISG15 is accomplished by the con-
certed action of the E1 enzyme for
ISG15 (UBE1L) and diverse E2 and
E3 ligases; removal of ISG15 chains
depends on the ISG15-specific iso-
peptidase UBP43. Targets for ISGyla-
tion include RIG-I, phospholipase C -g1,
Janus Kinase 1 (JAK1), and extra-
cellular signal-regulated kinase (ERK).
Although the exact mechanism by
which ISG15 conjugation results in an-
tiviral immunity remains a mystery, it is
clear that ISG15 is an important player
in the IFN response. Inmice, ISG15 ex-
pression inhibited Sindbis, influenza
A and B, herpes simplex, and murine
g-herpesvirus 68 replication (Lenschow
et al., 2007). Furthermore, ISG15 is se-
questered by the NS1 protein of influ-
enza B, resulting in a global decrease
in ISGylation that favors viral replication
(Yuan and Krug, 2001).368 Cell Host & Microbe 2, December 200From a virus ‘‘perspective,’’ inhibi-
tion of the host ubiquitination and
ISGylation systems can be doubly ad-
vantageous, as it allows simultaneous
downregulation of both the antiviral
and inflammatory responses. Further-
more, aspects of the adaptive immune
response—such as MHC class II ex-
pression—are also controlled by ubiq-
uitination and could be amenable to
viral manipulation. In this issue of Cell
Host & Microbe, Frias-Staheli et al.
(2007) elegantly demonstrate that
OTU-domain proteases from nairovi-
ruses and arteriviruses also act as
broad spectrum deISGylases and
deubiquitinases. Nairoviruses are neg-
ative strand, segmented RNA viruses
of the Bunyaviridae family, a group of
viruses known to cause several types
of hemorrhagic fever. Among them,
the Crimean Congo hemorrhagic fever
virus (CCHFV), Dugbe virus, and Nai-
robi sheep virus encode a large (L) pro-
tein that contains an RNA polymerase7 ª2007 Elsevier Inc.domain at the C terminus and an
OTU domain at the N-terminus. Simi-
larly, the arteriviruses equine arteritis
virus (EAV) and porcine respiratory
and reproductive syndrome virus
(PRRSV), which cause disease in
horses and pigs, encode an OTU do-
main protease in their nonstructural
protein 2 (nsp2). L and nsp2 proteins
primarily fulfill viral replication func-
tions—generation of viral mRNA/ge-
nome and viral polyprotein process-
ing, respectively. However, the study
by Frias-Staheli et al. (2007) reveals
a new common role for these unrelated
proteins in mediating viral immune
evasion by shutting down cellular
ubiquitination and ISGylation path-
ways. Sequence alignment of the
OTU domains from the viral proteases
and mammalian OTU domain deubiq-
uitinases (A20, Cezanne, VCIP135,
Otubain 1, and Otubain 2) revealed a
highly conserved motif, including the
catalytic residues C40 and H151. This
was the first indication that the viral
proteases may possess deubiquinat-
ing—and possibly deISGylating—ac-
tivity. This hypothesis was confirmed
by performing in vitro and in vivo
deISGylation and deubiquitination ex-
periments, which demonstrated that
transient overexpression of the CCHFV-L
or the arterivirus nsp2 proteins re-
sulted in a global reduction of ubiquiti-
nated and ISGylated proteins in the
host cell. Furthermore, mutation of
the catalytic cysteine residue (C40) to
alanine resulted in a marked decrease
in CCHFV-L protease activity, corrob-
orating the idea that the OTU domain
has bona fide deubiquitinase activity
(Figure 1). Thus, two distinct RNA viral
families utilize a similar viral evasion
strategy by encoding a multifunctional
viral protein containing an OTU do-
main with flexible deubiquitinase and
deISGylase activity that inhibits antivi-
ral signaling.
How effective is this evasionmecha-
nism? Using a recombinant Sindbis
virus model, which expressed ISG15
in tandem with either mutant or wild-
type OTU domain from CCHFV-L,
Frias-Staheli et al. (2007) showed that
it was very effective indeed. The ma-
jority of IFNa/b receptor knockout
mice (80%) infected with virulent Sid-
bis virus expressing ISG15 alone or
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infection, whereas mice infected with
virus expressing ISG15 plus wild-type
OTU domain succumbed to the
infection. This result correlated with a
decrease in ISGylated proteins in mice
infected with virus expressing the
wild-type OTU domain protease. Un-
fortunately, the authors were unable
to demonstrate the efficacy of this
strategy during the course of infection
of CCHFV or arteriviruses, thus leaving
open the question of just how pivotal
the OTU domain-containing proteases
are to the survival of these viruses. Fur-
ther work should address this issue in
the context of viral infection of the
natural host. Resolution of the crystal
structure of the viral OTU domain
would reveal determinants of sub-
strate promiscuity within the substrate
binding pocket, and mutation of key
residues should help determine if the
deISGylase or deubiquitinase activity
of the viral proteases can be specifi-
cally inhibited.
Deubiquitination of key signaling
molecules by specific or promiscuousviral DUBs could be envisioned as
a widespread mechanism of immune
evasion that provides the pathogen
a convenient means to simultaneously
silence the inflammatory and IFN re-
sponses. A global approach to the
identification of viral proteases capable
of cleaving ubiquitin chains would pro-
vide clues to the identity of other vi-
ruses that may utilize a similar immune
evasion strategy. Finally, the high rates
of mortality and the paucity of available
treatments highlight the unmetmedical
need for novel antiviral compounds.
This study argues that viral OTU do-
mains may be a relevant target for the
development of a new class of struc-
ture-directed antivirals. Small mole-
cule, viral OTU domain inhibitors could
afford protection against virus-induced
blockade of the innate immune re-
sponse and provide the host with the
opportunity to kick its viral guest OUT.REFERENCES
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